OUR PIPELINE

Focusing on making a difference in rare diseases with significant unmet need

Pipeline targeting rare kidney and metabolic disease

Program
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
FILSPARI®

(sparsentan)

Preclinical
Phase 1
Phase 2
Phase 3
Approved
Sparsentan
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Pegtibatinase

(TVT-058)

HCU
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Thiola EC® and Thiola®

(tiopronin)

Preclinical
Phase 1
Phase 2
Phase 3
Approved

THERAPEUTIC AREAS